

	•		CONFI	RMATION NO. 961
FILING DATE 11/22/2002 RULE	CLASS	GROUP AR	TIMU T	ATTORNEY DOCKET NO. TC00001P
ki, JAPAN; baraki, JAPAN; A ************************************	***		·	
Allowance Met afte	JAPAN	SHEETS DRAWING	TOTAL CLAIMS	L
	·			
nde				
IO Charge/credi	TO Charge/credit DEDOCIT AGOOD			cessing Ext. of
	11/22/2002 RULE RWA, Ibaraki, JAPAN; ki, JAPAN; baraki, JAPAN; A ************************************	TI1/22/2002 RULE RULE RAWA, Ibaraki, JAPAN; ki, JAPAN; baraki, JAPAN; A ************************************	TII/22/2002 RULE RULE ROUP AR ROUP A	FILING DATE 11/22/2002 CLASS GROUP ART UNIT RULE RAWA, Ibaraki, JAPAN; ki, JAPAN; baraki, JAPAN; A ************************************

"Express Mail" Mailing Label Number EL737872552US

Date Of Deposit 22 November 2002

I Hereby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.10 On The Date Indicated Above And Is Addressed To: Assistant Commissioner for Patents, Washington, D.C. 20231.

Name Of Person Mailing Paper Or Fo

(Type Or Print)

Signature__/

PROVISIONAL APPLICATION COVER SHEET

		ONAL AFE	LICH IIO	W TOLEW?	TEM I minde	er 37 CFR 1.53(c).	
			ket No.	TC000		T	
INVENTOR(s) / A	PPLICANT(s)						
Last Name	First Name	Middle	Resid	dence (Cit	tv and Eithe	er State or Foreign C	Country)
 		Initial					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HASEGAWA	Masaichi		Ibaraki	i, Japan			·
TANG	Jun	'		Ibaraki, Japan			
SATO	Hideyuki			i, Japan			
					-		
TITLE OF THE I	NVENTION (280	characters n	nax)				
		lovel Cher		ompou	nds	•	
				•			
Correspondence A							
GLAXOSMITH							
Corporate Intelle	ectual Property	- UW2220	j	Teler	nhone No	. 610-270-5009	
709 Swedeland Road						610-270-5099	
King of Prussia					1111110 1 10.	010-210-2020	,
State PA	Zip Code	19406-0	939	Country	United !	States of Americ	ig
						Jeneou On a manage	·a
ENCLOSED APPI	LICATION PART	S (check all	that apply	<u>, </u>			
ENCLOSED APPLICATION PARTS (check all that apply) Specification Number of Pages 67			1	Small Entity	Ctatamant		
		es $\frac{07}{1}$					
Abstract	Number of Pag	es	1 .	- 3	man Linuty	Statement	

ENCLOSED APP	LICATION PARTS (chec	ck all that apply)	
Specification Abstract	Number of Pages Number of Pages	67 1	Small Entity Statement	
☐ Drawings	Number of Sheets		Other (specify)	
Ine Commission	MENT OF FILING FEES For the series is hereby authorized to Deposit Account No. 19-25	VISIONAL APPLICATION FOR PATENT PROVISIONAL FILING \$160.6	<u></u>	

Respectfully submitted,

Signature:

Date:

Registration No.:

November 22, 2002

☐ Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

SEND TO: Assistant Commissioner for Patents, Box Provisional Application, Washington, D.C. 20231.

20462

PATENT TRADEMARK OFFICE

5

10

15

20

25

30

35

Novel Chemical Compounds

FIELD OF THE INVENTION

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.

BACKGROUND OF THE INVENTION

A number of polypeptide growth factors and hormones mediate their cellular effects through a signal transduction pathway. Transduction of signals from the cell surface receptors for these ligands to intracellular effectors frequently involves phosphorylation or dephosphorylation of specific protein substrates by regulatory protein serine/threonine kinases (PSTK) and phosphatases. Serine/threonine phosphorylation is a major mediator of signal transduction in multicellular organisms. Receptor-bound, membrane-bound and intracellular PSTKs regulate cell proliferation, cell differentiation and signalling processes in many cell types.

Aberrant protein serine/threonine kinase activity has been implicated or is suspected in a number of pathologies such as rheumatoid arthritis, psoriasis, septic shock, bone loss, many cancers and other proliferative diseases. Accordingly, serine/threonine kinases and the signal transduction pathways which they are part of are potential targets for drug design.

A subset of PSTKs are involved in regulation of cell cycling. These are the cyclindependent kinases or CDKs (Peter and Herskowitz, Cell 1994: 79, 181-184). CDKs are activated by binding to regulatory proteins called cyclins and control passage of the cell through specific cell cycle checkpoints. For example, CDK2 complexed with cyclin E allows cells to progress through the G1 to S phase transition. The complexes of CDKs and cyclins are subject to inhibition by low molecular weight proteins such as p16 (Serrano et al, Nature 1993: 366, 704), which binds to and inhibits CDK4. Deletions or mutations in p16 have been implicated in a variety of tumors (Kamb et al, Science 1994: 264, 436-440). Therefore, the proliferative state of cells and diseases associated with this state are dependent on the activity of CDKs and their associated regulatory molecules. In diseases such as cancer where inhibition of proliferation is desired, compounds that inhibit CDKs may be useful therapeutic agents. Conversely, activators of CDKs may be useful where enhancement of proliferation is needed, such

10

15

20

25

as in the treatment of immunodeficiency.

YAK1, a PSTK with sequence homology to CDKs, was originally identified in yeast as a mediator of cell cycle arrest caused by inactivation of the cAMP-dependent protein kinase PKA (Garrett et al, Mol Cell Biol. 1991: 11, 4045-4052). YAK1 kinase activity is low in cycling yeast but increases dramatically when the cells are arrested prior to the S-G2 transition. Increased expression of YAK1 causes growth arrest in yeast cells deficient in PKA. Therefore, YAK1 can act as a cell cycle suppressor in yeast.

Our US patent no. 6,323,318 describes two novel human homologs of yeast YAK1 termed hYAK3-2, one protein longer than the other by 20 amino acids. hYAK3-2 proteins (otherwise reported as REDK-L and REDK-S in Blood, 1 May 2000, Vol 95, No. 9, pp2838) are primarily localized in the nucleus. hYAK-2 proteins (hereinafter simply referred as hYAK3 or hYAK3 proteins) are present in hematopoietic tissues, such as bone marrow and fetal liver, but the RNA is expressed at significant levels only in erythroid or erthropoietin (EPO)-responsive cells. Two forms of REDK cDNAs appear to be alternative splice products. Antisense REDK oligonucleotides promote erythroid colony formation by human bone marrow cells, without affecting colonyforming unit (CFU)-GM, CFU-G, or CFU-GEMM numbers. Maximal numbers of CFU-E and burst-forming unit-erythroid were increased, and CFU-E displayed increased sensitivity to suboptimal EPO concentrations. The data indicate that REDK acts as a brake to retard erythropoiesis. Thus inhibitors of hYAK3 proteins are expected to stimulate proliferation of cells in which it is expressed. More particularly, inhibitors of hYAK3 proteins are useful to treat or prevent diseases of the erythroid and hematopoietic systems, caused by the hYAK3 imbalance including, but not limited to, neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; and myelosuppression.

30 SUMMARY OF THE INVENTION

In a first aspect, the instant invention relates a method of inhibiting hYAK3 in a mammal; comprising, administering to the mammal a therapeutically effective amount of a compound of the formula I, or a salt, solvate, or a physiologically functional derivative thereof

R is

10

5

15

20

Q is

in which Y is CH or N; and A and B together are a part of

provided that ortho position to Y is N or O; or

5

Q is

in which Y is N or CH; J is OH or -OC1-4alkyl; L is hydrogen, halogen, -NO2, or -OC1-4alkyl.

In a second aspect of the present invention, there is provided a compound of the formula II, or a salt, solvate, or a physiologically functional derivative thereof

20

25

II

in which

R is C₃₋₆ cycloalkyl or naphtyl; or

R is

30

in which R1 is halogen, -C₁₋₄alkyl, -SC₁₋₄alkyl, -OC₁₋₄alkyl, -NO₂, -S(=O)-C₁₋₄alkyl, -OH, -CF₃, -CN, -CO₂H, or -CO₂C₁₋₄alkyl; and R2 and R3 are independently hydrogen, halogen, -C₁₋₄ alkyl, -SC₁₋₄alkyl, -OC₁₋₄alkyl, -NO₂, -S(=O)-C₁₋₄alkyl, -OH, -CF₃, -CN, -CO₂H, -CO₂C₁₋₄alkyl; or

5 Ris

in which R4 is hydrogen or -SO2NH2; or

10 R is -(CH₂)_n-NR^kR^l in which n is 2 or 3, and R^k and R^l are independently -C₁₋₄alkyl; or -NR^kR^l together form

-N ; or

15

20

Ris

$$-N$$
, N , N

$$-N$$
 ; and

25

Q is

Q is

in which Y is CH or N; and A and B together are a part of

10

15

20

25

30.

provided that ortho position to Y is N or O.

In a third aspect of the present invention, there is provided a pharmaceutical composition including a therapeutically effective amount of a compound of formula I or II, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

In a fourth aspect of the present invention, there is provided the use of a compound of formula I or II, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment or prevention of a disorder of the erythroid and hematopoietic systems mediated the imbalance or inappropriate activity of hYAK3 proteins, including but not limited to, neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; and myelosuppression.

In a fifth aspect, the present invention relates to a method of treating or preventing diseases of the erythroid and hematopoietic systems, caused by the hYAK3 imbalance or inappropriate activity including, but not limited to, neutropenia; cytopenia;

anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; myelosuppression; comprising administering to a mammal a therapeutically effective amount of a compound of formula I or II, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

In a six aspect, the present invention relates to a method of treating or preventing neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; and myelosuppression; comprising administering to a mammal a therapeutically effective amount of a compound of formula I or Π , or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

15

20

25

30

10

5

DETAILED DESCRIPTION

As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or Furthermore, the term "therapeutically effective amount" means any clinician. amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

As used herein, the term "alkyl" refers to a straight or branched chain hydrocarbon. Furthermore, as used herein, the term "C14 alkyl" refers to an alkyl group as defined above containing at least 1, and at most 4, carbon atoms. Examples of branched or straight chained "C14 alkyl" groups useful in the present invention include methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, and t-butyl.

As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

As used herein, the term "C3.6 cycloalkyl" refers to a non-aromatic cyclic hydrocarbon ring having from three to six carbon atoms. Exemplary "C3.6 cycloalkyl" groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.

As used herein, the crisscrossed double bond indicated by the symbol denotes Z and/or E stereochemistry around the double bond. In other words a compound of formula I or II can be either in the Z or E stereochemistry around this double bond, or a compound of formula I or II can also be in a mixture of Z and E stereochemistry around the double bond. However, in formulas I and II, the preferred compounds have Z stereochemistry around the double bond to which radical Q is attached.

15

20

10

As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.

25

30

As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula I or II or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid. Most preferably the solvent used is water.

3

TC00001P

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

Certain of the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers. Accordingly, the compounds of this invention include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula I or II above as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted. Also, it is understood that all tautomers and mixtures of tautomers are included within the scope of the compounds of formula I or II.

15

20

25

30

35

Typically, the salts of the present invention are pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to nontoxic salts of the compounds of this invention. Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen on a substituent in the compound of formula I or II. Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, hydrobromide, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, phosphate/diphosphate, pantothenate, palmitate, (embonate), pamoate polygalacturonate, potassium, salicylate, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, trimethylammonium and valerate. Other salts, which are not pharmaceutically acceptable, may be useful in the preparation of compounds of this invention and these form a further aspect of the invention.

While it is possible that, for use in therapy, therapeutically effective amounts of a

compound of formula I or II, as well as salts, solvates and physiological functional derivatives thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the invention further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of the formula I or II and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of the formula I or II and salts, solvates and physiological functional derivatives thereof, are as described above. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula I or II, or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.

15

20

10

5

Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5mg to 1g, preferably 1mg to 700mg, more preferably 5mg to 100mg of a compound of the formula I or II, depending on the condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.

30

25

Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

Pharmaceutical formulations adapted for oral administration may be presented as 35 discrete units such as capsules or tablets; powders or granules; solutions or

5

10

15

20

25

30

35

suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a

screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

20

5

10

15

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

25

35

The compounds of formula I or II, and salts, solvates and physiological functional derivatives thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

30 stearylamine or phosphatidylcholine

The compounds of formula I or II, and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers

10

can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

- Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
- Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
- For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
- Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
- Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
 - Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.
- 35 Pharmaceutical formulations adapted for nasal administration wherein the carrier is a

solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.

10

5

Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. However, an effective amount of a compound of formula I or II for the treatment of or prevention of diseases of the erythroid and

hematopoietic systems, caused by hYAK3 imbalance or inappropriate activity including, but not limited to, neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; and myelosuppression will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula I or II per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.

15 Method of Preparation

10

20

25

30

35

Compounds of general formula I may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of formula I. Those skilled in the art will recognize if a stereocenter exists in compounds of formula I. Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers as well. compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).

More particularly, the compounds of the formula I can be made by the process of either Scheme A or B or a variant thereof. Any person skilled in the art can readily adapt the process of either A or B, such the stoichemistry of the reagents, temperature, solvents, etc. to optimize the yield of the products desired.

Scheme A

Briefly in Scheme A, a mixture of aniline derivative of formula II (1 equivalent) and NH4SCN (about 1.3 equivalent) in an acid (typically 4N-HCl) is heated to reflux at about 110 °C for 6 hours. After cooling, the mixture is treated with H2O, which process usually forms a solid, followed by desiccation in vacuo to give a compound of formula III.

A mixture of formula III compound, ClCH₂CO₂H (1 equivalent), and AcONa (1 equivalent) in AcOH is heated to reflux at around 110 Co for about 4 h. The mixture is poured onto water thereby a solid is typically formed, which is isolated by filtration. The solid is washed with a solvent such as MeOH to afford a compound of formula IV.

A mixture of formula IV compound, an aldehyde of formula V (1 equivalent), AcONa (3 equivalent) in AcOH is heated to reflux at about 110 Co for about 10 to 48 hours. After cooling, a small portion of water was added until the solid forms. The solid is

20

5

10

15

20

filtered and washed with a solvent such as MeOH, followed by desiccation in vacuo to afford a target product of formula I.

Briefly in Scheme B, a mixture of an aldehyde of formula V (1 equivalent), Rhodanine (1 equivalent), sodium acetate (about 3 equivalents), and acetic acid was heated at around 110 Co for about 48 h. The reaction mixture is cooled to room temperature to afford a product of formula VII.

Then, to a room temperature suspension of VII (1 equivalent) in a suitable solvent such as ethanol was added Hunig's base (about 2 equivalents) followed by iodomethane (about 5 equivalents). Stirring the resultant suspension at room temperature for 3.5 h will yield a compound of VIII.

To a mixture of VIII (1 equivalent) and MS4A powder was added an amine of formula IX (1-2 equivalent) and ethanol (dehydrated). The mixture was heated by microwave (SmithSynthesiser-Personal Chemistry) at about 110 °C for about 1200 seconds. Usually, the desired product of formula I can be obtained in about 20~90% yield after purification.

In Schemes A and B, the meaning of R and Q are as defined in formula I.

All the starting materials are either known, commercially available or can be readily made by a routine method. For example, an aldehyde of formula V in which the radical Q is of the formula

COVESSBY .112202

è

TC00001P

5

10

15

20

25

can be readily made by the following standard reduction or oxidation steps.

See Eur. J. Org. Chem.,1999, 2609~2621.

CHO 12 h

See J. Med. Chem., 2000, 43, 3878~3894.

 $Specific\ Embodiments-Examples$

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:

		•			
	g (grams);	mg (milligrams);			
	L (liters);	mL (milliliters);			
	μL (microliters);	psi (pounds per square inch);			
	M (molar);	mM (millimolar);			
5	i. v. (intravenous);	Hz (Hertz);			
	MHz (megahertz);	mol (moles);			
	mmol (millimoles);	rt (room temperature);			
	min (minutes);	h (hours);			
	mp (melting point);	TLC (thin layer chromatography);			
10	Tr (retention time);	RP (reverse phase);			
	MeOH (methanol);	i-PrOH (isopropanol);			
	TEA (triethylamine);	TFA (trifluoroacetic acid);			
	TFAA (trifluoroacetic anhydride);	THF (tetrahydrofuran);			
	DMSO (dimethylsulfoxide);	· · · · · · · · · · · · · · · · · · ·			
15	DME (1,2-dimethoxyethane);	AcOEt (ethyl acetate);			
	DCE (dichloroethane);	DCM (dichloromethane);			
		DMF (N,N-dimethylformamide); rea); (CDI (1,1-carbonyldiimidazole);			
	IBCF (isobutyl chloroformate);	HOAn (and it was a second distribution of the se			
	HOSu (N-hydroxysuccinimide);	HOAc (acetic acid);			
20	mCPBA (meta-chloroperhenzoic ac	HOBT (1-hydroxybenzotriazole);			
	BOC (tert-butyloxycarbonyl);	id; EDC (ethylcarbodiimide hydrochloride);			
	(dicyclohexylcarbodiimide);	FMOC (9-fluorenylmethoxycarbonyl); DCC			
	Ac (acetyl);	CBZ (benzyloxycarbonyl);			
	TMSE (2-(trimethylsilyl)ethyl);	atm (atmosphere);			
25	TIPS (triisopropylsilyl);	TMS (trimethylsilyl);			
		TBS (t-butyldimethylsilyl);			
30	DMAP (4-dimethylaminopyridine); ATP (adenosine triphosphate);	BSA (bovine serum albumin)			
	DMEM (Dulbergo's madis 17	HRP (horseradish peroxidase);			
	DMEM (Dulbecco's modified Eagle medium);				
	HPLC (high pressure liquid chromatography);				
	BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);				
	TBAF (tetra-n-butylammonium fluoride);				
	HBTU (O-Benzotriazole-1-yl-N,N,N',N'- tetramethyluronium				
	nexandoropnosphate).	• •			
35	HEPES (4-(2-hydroxyethyl)-1-pipera:	zine ethane sulfonic acid):			
J U	DPPA (diphenylphosphoryl azide);	· · · · · · · · · · · · · · · · · · ·			

fHNO3 (fumed HNO3); and EDTA (ethylenediaminetetraacetic acid).

All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted.

¹H NMR spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, a Brucker AVANCE-400, or a General Electric QE-300. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as a (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad).

15

20

5

10

Low-resolution mass spectra (MS) were recorded on a JOEL JMS-AX505HA, JOEL SX-102, or a SCIEX-APIiii spectrometer; LC-MS were recorded on a micromass 2MD and Waters 2690; high resolution MS were obtained using a JOEL SX-102A spectrometer. All mass spectra were taken under electrospray ionization (ESI), chemical ionization (CI), electron impact (EI) or by fast atom bombardment (FAB) methods. Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1-mm NaCl cell. Most of the reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck).

30

25

For ease of illustration, the regiochemistry around the double bonds in the chemical formula in the Examples are drawn as fixed; however, a skilled in the art will readily appreciate that the compounds will naturally assume the most thermodynamically stable structure around the C=N (the imine) double bond. Further it is intended that both E and Z isomers are encompassed around the C=C double bond.

5

10

15

20

Example 1 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)thiazolidin-4-one

A mixture of 2-chloro-5-fluoroaniline IIa (2.0 g, 13.7 mmol) and 1.7 g of NH₄SCN in 4N-HCl (20 mL) was heated to reflux at 110C° for 6 hours. After cooling, it was treated with H₂O to form a solid, followed by desiccation in vacuo to give thiourea IIIa (870 mg, 4.3 mmol). A mixture of IIIa (870 mg, 4.3 mmol), ClCH₂CO₂H (400 mg), and AcONa (350 mg) in AcOH (5 mL) was heated to reflux at 110 C° for 4 h. The mixture was poured onto water and the formed solid was isolated by filtration. It was washed with MeOH to give imino thiazolidinone IVa (456 mg, 1.9 mmol). A mixture of IVa (98 mg, 0.4 mmol), aldehyde Va (60 mg, 0.4 mmol), AcONa (100 mg) in AcOH (2 mL) was heated to reflux at 120 degree for 48 hours. After cooling, a small portion of water was added until the solid forms. It was filtered and washed with MeOH, followed by desiccation in vacuo to afford a target product Ia (61 mg, 0.16 mmol).

¹HNMR: (DMSO-d₆) δ 3.21 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.06 (sbr, 2H), 7.30 (d, 1H), 7.39 (s, 1H), 7.58 (sbr, 2H), 12.60 (sbr, 1H): LC/MS: m/z 375 (M+1), 377 (M+3)

Example 2-61 compounds were made by the process described in Scheme A, analogous to the method described in Example 1.

Example 2

 $\hbox{2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one}$

5 H NMR (DMSO-d₆) δ 6.52 (d, 1H), 7.15 (d, 1H), 7.21 (t, 1H), 7.38 (t, 1H), 7.49(d, 1H), 7.54 (d, 1H), 7.72 (s, 1H), 7.71-7.74 (m, 1H), 7.85 (s, 1H), 8.13 (d, 1H), 12.73 (s br, 1H): LC/MS: m/z 383 (M+1), 385 (M+3)

Example 3

2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 3.19 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.14 (d, 1H), 7.20 (t, 1H), 7.28 (d, 1H), 7.37 (m, 2H), 7.54 (d, 1H), 7.61 (s, 1H), 12.54 (brs, 1H): LC/MS: m/z 357 (M+1), 359(M+3)

Example 4

20

2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one

25 H NMR (DMSO-d₆) δ 2.06(s, 6H), 2.25 (s, 3H), 4.24 (dd, 4H), 6.94 (m, 4H), 6.96 (s, 1H), 7.52 (s, 1H), 12.5 (brs, 1H): LC/MS: m/z 381 (M+1)

Example 5 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one


5

1H NMR (DMSO-d₆) δ 2.05 (s, 6H), 2.24 (s, 3H), 3.19 (t, 2H), 4.56 (t, 2H), 6.84 (d, 1H), 6.91 (m, 2H), 7.22 (d, 1H), 7.31 (s, 1H), 7.51 (s, 1H), 12.5 (brs, 1H) : LC/MS: m/z 365 (M+1)

10 Example 6 2-Cyclohexylimino-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 1.18 (sbr, 1H), 1.31 (mbr, 2H), 1.59 (dbr, 1H), 1.72 (sbr, 2H), 1.93 (sbr, 2H), 3.89 (brs, 1H), 6.99 (d, 1H), 7.05 (m, 2H), 7.48 (s, 1H), 9.50 (dbr, 1H): LC/MS: m/z 345 (M+1)

Example 7
2-Cyclohexylimino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4one



 $^1\mathrm{H}$ NMR (DMSO-d₆) δ 1.19 (mbr, 1H), 1.29 (mbr, 2H), 1.57 (dbr, 1H), 1.72 (sbr, 2H), 1.91 (mbr, 2H), 3.24 (t, 2H), 3.89 (sbr, 1H), 4.60 (t, 2H), 6.91 (d, 1H), 7.33 (d, 1H), 7.43 (s, 1H), 7.53 (s, 1H), 9.45 (d. 1H) : LC/MS: m/z 329 (M+1)

25

Example 8

5-Benzo[1,3]dioxol-5-ylmethylene-2- (2-chloro-phenylimino)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 6.08 (d, 2H), 7.03 (m, 2H), 7.07 (s, 1H), 7.13 (d, 1H), 7.19 (t, 1H), 7.36 (t, 1H), 7.53 (d, 1H), 7.58 (s, 1H), 12.54 (sbr, 1H): LC/MS: m/z 359 (M+1),

Example 9

5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-o-tolylimino-thiazolidin-4-one

10

¹H NMR (DMSO-d₆) δ 2.14 (s, 3H), 3.19 (t, 2H), 4.57 (t, 2H), 6.86 (d, 1H), 6.93 (d, 1H), 7.10 (t, 1H), 7.22 (t, 1H), 7.27 (m, 2H), 7.35 (s, 1H), 7.57 (s, 1H), 12.24 (sbr, 1H): LC/MS: m/z 337 (M+1)

15 Example 10

 $5\hbox{-}(2,3\hbox{-}Dihydro-benzo [1,4] dioxin-6-ylmethylene)-2-o-tolylimino-thiazolidin-4-$

¹H NMR (DMSO-d₆) δ 2.14 (s, 3H), 4.23 (d, 2H), 4.26 (d, 2H), 6.96 (m, 2H), 7.00 (s, 1H), 7.11 (t, 1H), 7.22 (t, 1H), 7.29 (d, 1H), 7.53 (s, 1H), 12.29 (sbr, 1H): LC/MS: 20 m/z 353 (M+1)

5

Example 11 5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-3H-benzooxazol-2-one

 ^{1}H NMR (DMSO-d₆) δ 7.14 (d, 1H), 7.18 (s, 1H), 7.20 (t, 1H), 7.28 (d, 1H), 7.38 (m, 2H), 7.54 (d, 1H), 7.69 (s, 1H), 12.10 (sbr, 1H) : LC/MS: m/z 372 (M+1), 374 (M+3)

Example 12 2-(2-Bromo-phenylimino)-5-(2,8-dihydro-benzofuran-5-ylmethylene)thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 3.19 (t, 2H), 4.57 (t, 2H), 6.87 (d, 1H), 7.11 (m, 2H), 7.28 (d, 1H), 7.36 (s, 1H), 7.40 (t, 1H), 7.60 (s. 1H), 7.69 (d, 1H), 12.51 (sbr, 1H): LC/MS: m/z 401(M), 403 (M+2)

Example 13

20 ¹H NMR (DMSO-d₆) δ 3.19(t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.22 (d, 1H), 7.29 (d, 1H), 7.36 (m, 2H), 7.62 (s, 1H), 7.69 (t, 1H), 7.75 (d, 1H), 12.58 (sbr, 1H): LC/MS: m/z 391 (M+1)

Example 14 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one

5

1H NMR (DMSO-de) δ 3.20 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.20 (t, 1H), 7.28 (d, 1H), 7.36 (s, 1H), 7.55 (d, 1H), 7.64 (s, 1H), 12.77 (sbr, 1H): LC/MS: m/z 391 (M+1), 393 (M+3)

10 Example 15

 ${\bf 5\text{-}(2,3\text{-}Dihydro\text{-}benzofuran\text{-}5\text{-}ylmethylene)\text{-}2\text{-}(2\text{-}methylsulfanyl\text{-}phenylimino)\text{-}} thiazolidin\text{-}4\text{-}one}$

15

1H NMR (DMSO-d₆) δ 2.38 (s, 3H), 3.19 (t, 2H), 4.57 (t, 2H), 6.85 (d, 1H), 6.93 (d, 1H), 7.17 (m, 2H), 7.25 (m, 2H), 7.35 (s, 1H), 7.52 (s, 1H), 12.32 (sbr, 1H) : LC/MS: m/z 369 (M+1)

20 Example 16 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-fluoro-phenylimino)thiazolidin-4-one

25 ¹H NMR (DMSO-d₆) δ 3.20 (t, 2H), 4.58 (t, 2H), 6.88 (d, 1H), 7.15 (m, 1H), 7.21 (m, 2H), 7.29 (m, 2H), 7.38 (s, 1H), 7.61 (s, 1H): LC/MS: m/z 341 (M+1)

5

Example 17 2-(2-Methylsulfanyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 2.40 (s, 3H), 6.99 (d, 1H), 7.17-7.30 (m, 3H), 7.56 (dd, 1H), 7.83 (m, 2H), 8.08 (d, 1H), 8.13 (s, 1H), 8.46 (d, 1H), 8.92 (m, 1H), 12.65 (sbr, 1H): LC/MS: m/z 378 (M+1)

10 Example 18 2-(2-Bromo-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-de) δ 7.15 (t, 2H), 7.43 (t, 1H), 7.56 (dd, 1H), 7.71 (d, 1H), 7.83 (s, 1H), 7.86 (s, 1H), 8.08 (d, 1H), 8.14 (s, 1H), 8.44 (d, 1H), 8.93 (m, 1H), 12.77 (brs, 1H): LC/MS: m/z 410 (M), 412 (M+2)

Example 19 2-(2,3-Dimethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

20 ¹H NMR (DMSO-d₆) δ 2.07 (s, 3H), 2.27 (s, 3H), 6.81 (d, 1H), 7.03 (d, 1H), 7.12 (t, 1H), 7.55 (dd, 1H), 7.78 (s, 1H), 7.83 (dd, 1H), 8.06 (d, 1H), 8.11 (s, 1H), 8.42 (d, 1H), 8.92 (m, 1H): LC/MS: m/z 360 (M+1)

Example 20

2-(Naphthalen-1-ylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.17 (d, 1H), 7.54 (m, 4H), 7.80 (m, 2H), 7.82 (s, 1H), 7.97 (t, 2H), 8.03 (d, 1H), 8.09 (s, 1H), 8.38 (d, 1H), 8.90 (m, 1H): LC/MS: m/z 382 (M+1)

Example 21

 ${\bf 5\text{-}(Qu\bar{i}nolin-6\text{-}ylmethylene)\text{-}2\text{-}(2\text{-}trifluoromethyl-phenylimino)\text{-}thiazolidin-4-one}$

¹H NMR (DMSO-d₆) δ 7.23 (d, 1H), 7.36 (t, 1H), 7.55 (dd, 1H), 7.69 (t, 1H), 7.75 (d, 1H), 7.81 (s, 1H), 7.85 (d, 1H), 8.06 (d, 1H), 8.12 (s, 1H), 8.44 (d, 1H), 8.92 (d, 1H), 12.80 (sbr, 1H) : LC/MS: m/z 400 (M+1)

15 Example 22

10

2-(2-Chloro-5-trifluoromethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

1H NMR (DMSO-d₅) δ 7.50-7.60 (mbr, 2H), 7.56 (dd, 1H), 7.70-7.95 (mbr, 3H), 8.07
 20 (d, 1H), 8.14 (s, 1H), 8.44 (d, 1H), 8.92 (m, 1H), 12.89 (sbr, 1H): LC/MS: m/z 434 (M+1), 436 (M+3)

Example 23

2-(2,6-Dichloro-phenylimino)-5-8quinolin-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.23 (t, 1H), 7.55 (m, 3H), 7.84 (d, 1H), 7.87 (s, 1H), 8.08 (d, 1H), 8.14 (s, 1H), 8.46 (d, 1H), 8.93 (m, 1H), 13.01 (sbr, 1H): LC/MS: m/z 400 (M+1), 402 (M+3)

Example 24

2-(2-Bromo-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)

10 thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 4.25 (m, 4H), 6.97 (m, 3H), 7.13 (t, 2H), 7.42 (t, 1H), 7.57 (s, 1H), 7.70 (d, 1H), 12.60 (sbr, 1H): LC/MS: m/z 417 (M), 419 (M+2)

Example 25

5- (Benzo [1,3] diox ol-5-ylmethylene) -2- (2-bromo-phenylimino) -thiazolidin-4-brown

20

15

¹H NMR (DMSO-d₆) δ 6.09 (s, 2H), 7.03 (m, 3H), 7.13 (m, 2H), 7.41 (t, 1H), 7.60 (s, 1H), 7.69 (d, 1H), 12.60 (sbr, 1H)

Example 26

2-(2-Chloro-phenylimino)-5-(quinoxalin-6-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.19 (d, 1H), 7.23 (t, 1H), 7.39 (t, 1H), 7.56 (d, 1H), 7.92 (s, 1H), 7.98 (dd, 1H), 8.17 (m, 2H), 8.97 (s, 2H), 12.84 (sbr, 1H): LC/MS: m/z 367 (M+1), 369 (M+3)

 $\hbox{2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzo[1,4] dioxin-6-ylmethylene)-}$

10 thiazolidin-4-one

 1 H NMR (DMSO-d₆) δ 4.25 (m, 4H), 6.97 (s, 2H), 7.02 (s, 1H), 7.22 (t, 1H), 7.55 (d, 2H), 7.60 (s, 1H), 12.84 (sbr, 1H) : LC/MS: m/z 407 (M+1), 409 (M+3)

15 Example 28

5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-2-(2-nitro-phenylimino) thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 4.26 (m, 4H), 6.96 (d, 1H), 7.03 (m, 2H), 7.31 (d, 1H), 7.38 (t, 1H), 7.58 (s, 1H), 7.72 8t, 1H), 8.01 (d, 1H), 12.66 (sbr, 1H): LC/MS; m/z 384 (M+1) 20

Example 29 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-nitro-phenylimino)-thiazolidin-4-one

5 ¹H NMR (DMSO-ds) δ 3.20 (t, 2H), 4.58 (t, 2H), 6.88 (d, 1H), 7.30 (d, 2H), 7.39 (m, 2H), 7.64 (s, 1H), 7.73 (t, 1H), 8.03 (d, 1H), 12.63 (sbr, 1H) : LC/MS: m/z 368 (M+1)

Example 30 2-(2-Chloro-4-fluoro-5-methyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-10 ylmethylene)-thiazolidin-4-one

15

¹H NMR (DMSO-d₆) δ 2,22 (s, 3H), 3.20 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.05 (d, 1H), 7.28 (d, 1H), 7.38 (s, 1H), 7.44 (d, 1H), 7.58 (s, 1H), 12.43 (sbr, 1H): LC/MS: m/z 389 (M+1), 391 (M+3)

Example 31 3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid methyl ester

20 ¹H NMR (DMSO-d₆) δ 3.20 (t, 2H), 3.87 (s, 3H), 4.57 (t, 2H), 6.85 (d, 1H), 7.29 (d, 1H), 7.38 (mbr, 2H), 7.52 (s, 1H), 7.88 (d, 1H), 7.99 (s, 1H), 12.4 (sbr, 1H): LC/MS: m/z 415 (M+1), 417 (M+3)

Example 32 2-(2-Chloro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one

5 ¹H NMR (DMSO-d₆) δ 4.25 (dd, 4 H), 6.94-7.01 (m, 3H), 7.14 (d, 1H), 7.20 (t, 1H), 7.37 (t, 1H), 7.54 (d, 1H), 7.57 (s, 1H), 12.6 (s br, 1H): LC/MS: m/z 373 (M+1), 375 (M+3)

10 Example 33 2-(2-Chloro-4-trifluoromethyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 3.20 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.30 (d, 1H), 7.37 (m, br), 7.40 (s, 1H), 7.62 (s, 1H), 7.73 (d, 1H), 7.95 (s, 1H), 12.68 (sbr, 1H): LC/MS: m/z 425 (M+1), 427 (M+3)

Example 34 2-(4-Bromo-2-chloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 3.20 (t, 2H), 4.57 (t, 2H), 6.85 (d, 1H), 7.07 (sbr, 1H), 7.28 (d, 1H), 7.37 (s, 1H), 7.51 (mbr, 2H), 7.76 (mbr, 1H), 12.07 (sbr, 1H): LC/MS: m/z 436 (M+1)

25

Example 35 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-methanesulfinyl-phenylimino)-thiazolidin-4-one

5 H NMR (DMSO-d₆) δ 2.68 (s, 3H), 3.20 (t, 2H), 4.58 (t, 2H), 6.87 (d, 1H), 7.18 (d, 1H), 7.31 (d, 1H), 7.39 (s, 1H), 7.46 (t, 1H), 7.57 (t, 1H), 7.63 (s, 1H), 7.80 (d, 1H) : LC/MS: m/z 385 (M+1)

Example 36
3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid

15

 1H NMR (DMSO-d₆) δ 3.20 (t, 2H), 4.55 (t, 2H), 6.82 (d, 1H), 7.25 (d, 1H), 7.28 (mbr, 2H), 7.36 (s, 1H), 7.73 (d, 1H), 7.86 (s, 1H): LC/MS: m/z 401 (M+1), 403 (M+3)

Example 37 5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-1H-pyridin-2-one

20 ¹H NMR (DMSO-d₆) δ 6.40 (m, 1H), 7.07 (d, 1H), 7.13 (t, 1H), 7.32 (t, 1H), 7.38 (s, 1H), 7.50 (t, 2H), 7.77 (s, 1H), 12.07 (sbr, 1H): LC/MS: m/z 332 (M+1), 334 (M+3)

Example 38 2-(2-Methylsulfanyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one

5 ¹H NMR (DMSO-d₆) δ 2.40 (s, 3H), 7.17-7.28 (m, 3H), 7.55 (dd, 1H), 7.80 (s, 1H), 7.84 (d, 1H), 8.07 (d, 1H), 8.12 (s, 1H), 8.42 (d, 1H), 8.92 (m, 1H), 12.56 (sbr, 1H): LC/MS: m/z 378 (M+1)

Example 39

2-(2-Chloro-4-fluoro-5-methyl-phenylimino)-5-(quinolin-6-ylmethylene)thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 2.23 (s, 3H), 7.10 (d, 1H), 7.48 (d, 1H), 7.57 (dd, 1H), 7.83 (s, 1H), 7.86 (dd, 1H), 8.08 (d, 1H), 8.14 (s, 1H), 8.46 (d, 1H), 8.93 (m, 1H), 12.69 (sbr, 1H): LC/MS: m/z 398 (M+1), 400 (M+3)

Example 40

 $\hbox{$2$-(2-Chloro-5-fluoro-phenylimino)-5-(quino lin-6-ylmethylene)-thiazolidin-4-one}$

20

¹H NMR (DMSO-d₆) δ 7.10 (sbr, 2H), 7.56 (dd, 1H), 7.58 (mbr, 1H), 7.82 (s, 1H), 7.88 (m, 1H), 8.07 (d, 1H), 8.14 (s, 1H), 8.46 (d, 1H), 8.93 (d, 1H), 12.81 (sbr, 1H) : LC/MS: m/z 384 (M+1), 386 (M+3)

10

Example 41 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one

5 ¹H NMR (DMSO-d₆) δ 4.26 (m, 4H), 6.95 (d, 1H), 7.02 (d, 1H), 7.05 (mbr, 3H), 7.55 (mbr, 2H), 12.65 (sbr, 1H): LC/MS: m/z 391 (M+1), 393 (M+3)

Example 42 2-(2-Chloro-4-trifluoromethyl-phenylimino)-5-(quinoxalin-6-ylmethylene)thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.41 (d, 1H), 7.57 (dd, 1H), 7.76 (d, 1H), 7.87 (m, 2H), 7.99 (s, 1H), 8.08 (d, 1H), 8.17 (s, 1H), 8.47 (d, 1H), 8.94 (dd, 1H), 12.90 (sbr, 1H): LC/MS: m/z 435 (M+1), 437 (M+3)

15 Example 43 5-(Benzothiazol-6-ylmethylene)-2-(2-chloro-phenylimino)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.14 (d, 1H), 7.20 (t, 1H), 7.37 (t, 1H), 7.53 (d, 1H), 7.65 (d, 20 1H), 7.77 (s, 1H), 8.14 (d, 1H), 8.36 (s, 1H), 9.47 (s, 1H), 12.61 (sbr, 1H): LC/MS: m/z 372 (M+1), 374 (M+3)

Example 44 5-(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-bromo-phenylimino)-thiazolidin-4-one

5 ¹H NMR (DMSO-d₆) δ 7.15 (m, 2H), 7.43 (t, 1H), 7.71 (d, 1H), 7.83 (dd, 1H), 7.89 (s, 1H), 8.16 (d, 1H), 8.22 (s, 1H), 12.83 (sbr, 1H): LC/MS: m/z 417 (M), 419 (M+2)

Example 45

10

5-(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-chloro-5-fluoro-phenylimino)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.11 (m, 2H), 7.60 (t, 1H), 7.85 (d, 1H), 7.89 (s, 1H), 8.16 (d, 1H), 8.25 (s, 1H), 12.89 (sbr, 1H): LC/MS: m/z 391 (M+1), 393 (M+3)

15 Example 46

 ${\bf 5\hbox{-}(Benzothiazol\hbox{-}6\hbox{-}ylmethylene)\hbox{-}2\hbox{-}(2,6\hbox{-}dichloro\hbox{-}phenylimino)\hbox{-}thiazolidin-4\hbox{-}one}$

¹H NMR (DMSO-d₆) δ 7.23 (t, 1H), 7.57 (d, 2H), 7.66 (d, 1H), 7.86 (s, 1H), 8.15 (d, 1H), 8.39 (s, 1H), 9.49 (s, 1H), 12.98 (sbr, 1H) : LC/MS: m/z 406 (M+1), 408 (M+3)

Example 47

2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-nitro-benzylidene)-thiazolidin-4-one

¹H NMR (DMSO-d₆) δ 7.14 (d, 1H), 7.22 (m, 2H), 7.38 (t, 1H), 7.54 (d, 1H), 7.62 (d, 1H), 7.67 (s, 1H), 8.08 (s, 1H), 11.75 (sbr, 1H), 12.69 (sbr, 1H): LC/MS: m/z 376 (M+1), 378 (M+3)

10

Example 48

 $\textbf{2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-methoxy-benzylidene)-thiazolidin-4-one \\$

15

¹H NMR (DMSO-d₆) δ 3.75 (s, 3H), 6.88 (m, 2H), 7.15 (t, 1H), 7.19 (t, 1H), 7.36 (t, 1H), 7.53 (d, 1H), 7.58 (s, 1H), 9.80 (sbr, 1H), 12.30 (sbr, 1H) : LC/MS: m/z 361 (M+1), 363 (M+3)

20

Example 49

 ${\bf 2\text{-}(2\text{-}Chloro\text{-}phenylimino)\text{-}5\text{-}(4\text{-}hydroxy\text{-}2\text{-}methoxy\text{-}benzylidene)\text{-}thiazolidin\text{-}4\text{-}one}}$

25

 1H NMR (DMSO-d₆) δ 3.81 (s, 3H), 6.47 (m, 2H), 7.10 (m, 2H), 7.19 (t, 1H), 7.35 (t, 1H), 7.53 (d, 1H), 7.83 (s,1H), 10.30 (sbr, 1H), 12.21 (sbr, 1H) 360

 $\begin{array}{l} {\bf Example~50} \\ {\bf 2\hbox{-}(2\hbox{-}Chloro\hbox{-}phenylimino)\hbox{-}5\hbox{-}(4\hbox{-}hydroxy\hbox{-}benzylidene)\hbox{-}thiazolidin-4\hbox{-}one} \end{array}$

5 ¹H NMR (DMSO-d₆) δ 6.86 (d, 2H), 7.13 (d, 1H), 7.20 (t, 1H), 7.34 (d, 2H), 7.36 (m, 1H), 7.53 (d, 1H), 7.58 (s, 1H), 10.20 (sbr, 1H), 12.48 (sbr, 1H): LC/MS: m/z 331 (M+1), 333 (M+3)

Example 51
10 2-(2-Chloro-phenylimino)-5-(4-methoxy-benzylidene)-thiazolidin-4-one

 1H NMR (DMSO-de) δ 3.78 (s, 3H), 7.05 (d, 2H), 7.14 (m, 1H), 7.21 (t, 1H), 7.37 (t, 1H), 7.46 (d, 2H), 7.54 (d, 1H), 7.63 (s, 1H), 12.54 (sbr, 1H) : LC/MS: m/z 345 (M+1), 347 (M+3)

Example 52 5-(3-Chloro-4-hydroxy-benzylidene)-2-(2-chloro-phenylimino)-thiazolidin-4one

15

20 ¹H NMR (DMSO-d₆) δ 7.06 (d, 1H), 7.14 (d, 1H), 7.21 (t, 1H), 7.28 (d, 1H), 7.37 (t, 1H), 7.55 (m, 3H), 11.02 (sbr, 1H), 12.0 (sbr, 1H): LC/MS: m/z 365 (M+1), 367 (M+3)

 $\begin{tabular}{l} Example 53 \\ 2-(2-Chloro-phenylimino)-5-(3-fluoro-4-methoxy-benzylidene)-thiazolidin-4-methoxy-benzylidene) \end{tabular}$

 5 ^{1}H NMR (DMSO-d₆) δ 7.13 (d, 1H), 7.19 (t, 1H), 7.28 (m, 2H), 7.36 (t, 1H), 7.40 (d, 1H), 7.53 (d, 1H), 7.58 (s, 1H), 12.59 (sbr, 1H) 2

Example 54

2-(2,6-Dichloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-

¹H NMR (DMSO-d₆) δ 7.03 (t, 1H), 7.12 (mbr, 2H), 7.30 (d, 1H), 7.50 (mbr, 3H), 12.08 (sbr, 1H): LC/MS: m/z 383 (M+1), 385 (M+3)

Example 55

15

2-(2-Chloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-

20 ¹H NMR (DMSO-d₆) δ 7.05 (t, 1H), 7.14 (d, 1H), 7.21 (t, 1H), 7.37 (m, 2H), 7.54 (d, 1H), 7.58 (s, 1H), 10.67 (sbr, 1H), 12.11 (sbr, 1H): LC/MS: m/z 349 (M+1), 351 (M+3)

Example 56 2-(2-Chloro-5-fluoro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one

5 H NMR (DMSO-d₆) δ 7.04-7.13 (m, 3H), 7.17 (d, 1H), 7.39 (d, 1H), 7.60 (m, 2H), 10.69 (sbr, 1H), 12.00 (sbr, 1H): LC/MS: m/z 367 (M+1), 369 (M+3)

Example 57 5-(3-Fluoro-4-hydroxy-benzylidene)-2-o-tolylimino-thiazolidin-4-one

10

1H NMR (DMSO-d₆) δ 2.14 (s, 3H), 6.94 (d, 1H), 7.04 (t, 1H), 7.12 (m, 2H), 7.23 (t, 1H), 7.28 (d, 1H), 7.33 (d, 1H), 7.54 (s, 1H), 10.66 (sbr, 1H), 12.12 (sbr, 1H) : LC/MS: m/z 329 (M+1)

15 Example 58

20

 $\hbox{2-}(2-Chloro-phenylimino)-5-quino lin-6-ylmethylene-thia zolidin-4-one$

1H NMR (400MHz, DMSO-ds) ppm 7.17-7.25 (m, 2H), 7.39 (m, 1H), 7.57 (m, 2H), 7.84 (m, 1H), 7.86 (s, 1H), 8.08 (d, 1H, J = 8.8Hz), 8.14 (s, 1H), 8.45 (d, 1H, J = 7.8Hz), 8.93 (m, 1H). LC/MS: m/z 366 (M+1)+, 364 (M-1) -.

Example 59

5-Quinolin-6-ylmethylene-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one

1H NMR (400MHz, DMSO-d6) ppm 2.15 (s, 6H), 2.27 (s, 3H), 6.95 (s, 2H), 7.56 (m, 1H), 7.81 (m, 2H), 8.07 (d, 1H, J = 8.8 Hz), 8.11 (s, 1H), 8.42 (d, 1H, J = 8.4 Hz), 8.92 (m, 1H). LC/MS: m/z 374 (M+1)+, 372 (M-1) -.

Example 60

${\bf 5-Quinolin-6-ylmethylene-2-o-tolylimino-thiazolidin-4-one}$

NH S-NH

10

б

1H NMR (400MHz, DMSO-d6) ppm 2.17 (s, 3H), 6.98 (m, 1H), 7.14 (m, 1H), 7.22-7.31 (m, 2H), 7.56 (m, 1H), 7.81 (s, 1H), 7.83 (m, 1H), 8.07 (d, 1H, J = 8.8 Hz), 8.12 (s, 1H), 8.42 (d, 1H, J = 7.6 Hz), 8.92 (m, 1H), 12.47 (m, 1H). LC/MS: m/z 346 (M+1)+, 344 (M-1)-.

Example 61

 $\hbox{2-(2-Methoxy-phenylimino)-5-quino lin-6-ylmethyle ne-thiazolidin-4-one}$

5 A mixture of E, Z-isomers(ratio = 3.0/1.0)

1H NMR (400MHz, DMSO-d₆) ppm 3.78 (s, 2.25H), 3.90 (s, 0.75H), 6.97-7.28 (m, 3H), 7.56 (m, 0.75H), 7.62 (m, 0.25H), 7.81-7.86 (m, 2H), 7.94-8.24 (m, 3H), 8.42-8.51 (m, 1H), 8.92 (m, 0.75H), 8.96 (m, 0.25H), 12.44 (m, 1H). LC/MS: m/z 362 (M+1)+, 360 (M-1)-.

10

Example 62

 $5\hbox{-}(2,3\hbox{-}Dihydro-benzofur an-}5\hbox{-}ylmethylene)-2\hbox{-}(2\hbox{-}dimethylamino-ethylamino)-thiazol-}4\hbox{-}one$

10

15

20

25

A mixture of aldehyde of formula Va (10 mmol), Rhodanine VIa (10 mmol), sodium acetate (30 mmol), and 10 mL of acetic acid was heated at 110°C for 48 h. The reaction mixture was cooled to room temperature and filtered to collect the precipitate formed. The precipitate was washed with acetic acid (1 mL), methanol (1 mL) and dried in vaccuo to give compound VIIa 3.9g (14.81 mmol).

To room a temperature suspension of VIIa (14.81 mmol) in 100 mL ethanol was added Hunig's base (5.2 mL, 29.85 mmol) followed by iodomethane (4.6 mL, 73.9 mmol). After stirring the resultant suspension at room temperature for 3.5 h, the precipitate was filtered and washed with water to afford compound VIIIa 3.12g (11.25 mmol) as a first crop. After evaporating the filtrate, to the residue was added methanol (10 mL) and water (10 mL), and the resultant mixture was subjected to sonication for 1 min. The process yielded the second crop which was filtered. 0.8g (2.89 mmol).

To a mixture of VIIIa (0.3 mmol) and MS4A (molecular sieve 4 Angstrom powder) (250 mg) was added dimethylaminoethylamine (0.45 mmol) and ethanol (1mL, dehydrated). The mixture was heated by microwave (SmithSynthesiser-Personal Chemistry) at 110 Co for 1200 seconds. The corresponding product was obtained in 65% yield after purification on SCX column.

1H NMR (400MHz, DMSO-d₆) ppm 2.18 (s, 6H), 2.44 (t, 2H, J = 6.6 Hz), 3.24 (t, 2H, J = 8.6 Hz), 3.58 (t, 2H, J = 6.6 Hz), 4.60 (t, 2H, J = 8.6 Hz), 6.90 (d, 1H, J = 8.3 Hz), 7.30-7.48 (m, 3H). LC/MS: m/z 318 (M+1)+, 316 (M-1) -.

Example 63-72 compounds were made according to the process B, analogous to the method described in Example 62.

Example 63

acid N'-(4-oxo-5-quinolin-6-ylmethylene-4,5-dihydro-thiazol-2-yl)-Benzoic hydrazide

- 1H NMR (400MHz, DMSO-ds) ppm 7.49-7.63 (m, 4H), 7.84 (s, 1H), 7.91-7.97 (m, 3H), 8.12 (d, 1H, J = 8.8 Hz), 8.23 (d, 1H, J = 2.0 Hz), 8.48 (d, 1H, J = 7.8 Hz), 8.95 (m, 1H), 5 11.17 (s, 1H), 12.63 (br, 1H). LC/MS: m/z 375 (M+1)+, 373 (M-1) -.
- Example 64 10

 $\hbox{\bf 2-(2-Dimethylamino-ethylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one}$

1H NMR (400MHz, CDsOD) ppm 2.80 (s, 6H), 8.24 (t, 2H, J = 6.0 Hz), 3.94 (t, 2H, J = 6.0 Hz), 7.57 (m, 1H), 7.88-7.91 (m, 2H), 8.04-8.08 (m, 2H), 8.37-8.45 (m, 2H), 8.86 (dd, 1H, J = 1.8, 4.6 Hz). LC/MS: m/z 327 (M+1)+, 325 (M-1) -. 15

Example 65

 ${\bf 5\text{-}(2,3\text{-}Dihydro\text{-}benzofuran\text{-}5\text{-}ylmethylene)\text{-}2\text{-}(piperidin\text{-}1\text{-}ylamino)\text{-}thiazol\text{-}4\text{-}}.}$ one

5 1H NMR (400MHz, DMSO-d₆) ppm 1.40 (br, 2H), 1.63 (m, 4H), 2.27 (m, 4H), 3.26 (t, 2H, J = 8.6 Hz), 4.61 (t, 2H, J = 8.6 Hz), 6.93 (d, 1H, J = 8.4 Hz), 7.37 (dd, 1H, J = 1.8, 8.4 Hz), 7.47 (s, 1H), 7.51 (s, 1H), 11.68 (br, 1H). LC/MS: m/z 330 (M+1)+, 328 (M-1) -.

10 Example 66

2-Benzylamino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one

1H NMR (400MHz, DMSO-d₆) ppm 3.25 (t, 2H, J = 8.6 Hz), 4.60 (t, 2H, J = 8.6 Hz), 4.73 (s, 2H), 6.92 (d, 1H, J = 8.4 Hz), 7.29-7.57 (m, 8H), 9.97 (br, 1H). LC/MS: m/z 337 (M+1)+, 335 (M-1) -.

Example 67

 $\hbox{2-(4-tert-Butyl-thiazol-2-ylamino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one}$

5 1H NMR (400MHz, DMSO-d₆) ppm 1.35 (s, 9H), 3.24 (t, 2H, J = 8.6 Hz), 4.64 (t, 2H, J = 8.6 Hz), 6.93 (d, 1H, J = 8.3 Hz), 7.02 (s, 1H), 7.46 (dd, 1H, J = 1.8, 8.3 Hz), 7.57 (br, 1H), 7.65 (s, 1H), 12.53 (s, 1H). LC/MS: m/z 386 (M+1)+, 384 (M-1) -.

Example 68

4-{[5-(2,3-Dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-ylamino]-methyl}-benzenesulfonamide

Example 69

5-(2,3-Dihydro-benzo furan-5-ylmethylene)-2-(3-dimethylamino-propylamino)-thiazol-4-one

5 1H NMR (400MHz, DMSO-ds) ppm 1.74 (m, 2H), 2.13 (s, 6H), 2.25 (t, 2H, J = 6.8 Hz), 3.24 (t, 2H, J = 8.6 Hz), 3.51 (t, 2H, J = 6.8 Hz), 4.61 (t, 2H, J = 8.6 Hz), 6.91 (d, 1H, J = 8.3 Hz), 7.57-7.52 (m, 3H). LC/MS: m/z 332 (M+1)+, 330 (M-1) -.

Example 70

5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(3-imidazol-1-yl-propylamino)thiazol-4-one

1H NMR (400MHz, DMSO-d₆) ppm 2.04 (m, 2H), 3.25 (t, 2H, J = 8.8 Hz), 3.45 (t, 2H, J = 7.0 Hz), 4.04 (t, 2H, J = 7.0 Hz), 4.61 (t, 2H, J = 8.8 Hz), 6.91 (s, 1H), 6.92 (d, 1H, J = 8.6 Hz), 7.22 (t, 1H, J = 1.3 Hz), 7.34 (dd, 1H, J = 1.5, 8.3 Hz), 7.43 (s, 1H), 7.55 (s, 1H), 7.66 (m, 1H), 9.57 (br, 1H). LC/MS: m/z 355 (M+1)+, 353 (M-1) -.

Example 71

Phenyl-carbamic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-yl]-hydrazide

1H NMR (400MHz, DMSO-d₆) ppm 3.26 (t, 2H, J = 8.8 Hz), 4.62 (t, 2H, J = 8.8 Hz), 6.93-7.01 (m, 2H), 7.24-7.62 (m, 6H), 9.17 (s, 1H). LC/MS: m/z 381 (M+1)+, 379 (M-1) -.

Example 72

Benzoic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-yl]-hydrazide

10

1H NMR (400MHz, DMSO-d₆) ppm 3.23 (t, 2H, J = 8.6 Hz), 4.60 (t, 2H, J = 8.6 Hz), 6.91 (d, 1H, J = 8.3 Hz), 7.37 (dd, 1H, J = 1.5, 8.3 Hz), 7.47-7.61 (m, 5H), 7.90 (d, 2H, J = 7.3 Hz), 11.08 (s, 1H), 12.49 (br, 1H). LC/MS: m/z 355 (M+1)+, 353 (M-1) -.

15 Biological Methods and Data

As demonstrated by the representative compounds of the present invention in Table 1, the compounds of the present invention have valuable pharmacological properties due

10

15

20

25

30

35

to their potent ability to inhibit the hYAK3 kinase enzyme.

Substrate phosphorylation assays were carried out as follows:

YAK3 Scintillation Proximity Assays Using Ser164 of Myelin Basic Protein as the phosphoacceptor

The source of Ser164 substrate peptide The biotinylated Ser164, S164A peptide(Biotinyl -LGGRDSRAGS*PMARR-OH), sequence derived from the Cterminus of bovine myelin basic protein (MBP) with Ser162 substituted as Ala162, was purchased from California Peptide Research Inc. (Napa, CA), and its purity was determined by HPLC. Phosphorylation occurs at position 164 (marked S* above). The calculated molecular mass of the peptide was 2166 dalton. Solid sample was dissolved at 10 mM in DMSO, aliquoted, and stored at -20 °C until use.

The source of enzyme:

hYAK3: Glutathione-S-Transferase (GST)-hYak3-His6 containing amino acid residues 124-526 of human YAK3 (as 124-526 of SEQ ID NO 2. in US patent no. 6,323,318) was purified from baculovirus expression system in Sf9 cells using Glutathione Sepharose 4B column chromatography followed by Ni-NTA-Agarose column chromatography. Purity greater than 65% typically was achieved. Samples, in 50 mM Tris, 150 mM NaCl, 10%glycerol, 0.1% Triton, 250 mM imidazole, 10 mM β -mercapto ethanol, pH 8.0. were stored at -80 °C until use.

Kinase assay of purified hYAK3: Assays were performed in 96 well (Costar, Catalog No. 3789) or 384 well plates (Costar, Catalog No. 3705). Reaction (in 20, 25, or 40 μ l volume) mix contained in final concentrations 25 mM Hepes buffer, pH 7.4; 10 mM MgCl₂; 10 mM β -mercapto ethanol; 0.0025% Tween-20; 0.001 mM ATP, 0.1 μ Ci of [γ -33P]ATP; purified hYAK3 (7-14 ng/assay; 4 nM final); and 4 μ M Ser164 peptide. Compounds, titrated in DMSO, were evaluated at concentrations ranging from 50 μ M to 0.5 nM. Final assay concentrations of DMSO did not exceed 5%, resulting in less than 15% loss of YAK3 activity relative to controls without DMSO. Reactions were incubated for 2 hours at room temperature and were stopped by a 75 ul addition of 0.19 μ g Streptavidin Scintillation Proximity beads (Amersham Pharmacia Biotech, Catalog No. RPNQ 0007) in PBS, pH 7.4, 10 mM EDTA, 0.1% Triton X-100, 1 mM ATP. Under the assay conditions defined above,

the K_m(apparent) for ATP was determined to be 7.2 +/- 2.4 µM.

Table 1

Example No. compounds	plC ₅₀ values
18	++++
23	++++
46	+++
13	++
64	+

Legend.

plC ₅₀ values	Symbol
10 - 9	++++
8.99 – 8	+++
7.99 - 7	++
6.99 – 6	+

 $pIC_{50} = -log_{10}(IC_{50})$

5

Utility of the Present Invention

The above biological data clearly shows that the compounds of formula I or II are useful for treating or preventing disease states in which hYAK3 proteins are implicated, especially diseases of the erythroid and hematopoietic systems, including anemias due to renal insufficiency or to chronic disease, such as autoimmunity or cancer and drug-induced anemias, polycythemia, myelodysplastic syndrome, aplastic anemia and myelosuppression; cytopenia.

15

The compounds of formula I or II are especially useful in treating diseases of the

5

10

hematopoietic system, particularly anemias. Such anemias include an anemia selected from the group comprising: aplastic anemia and myelodysplastic syndrome. Such anemias also include those wherein the anemia is a consequence of a primary disease selected from the group consisting of: cancer, leukemia and lymphoma. Such anemias also include those wherein the anemia is a consequence of a primary disease selected from the group consisting of: renal disease, failure or damage. Such anemias include those wherein the anemia is a consequence of chemotherapy or radiation therapy, in particular wherein the chemotherapy is chemotherapy for cancer or AZT treatment for HIV infection. Such anemias include those wherein the anemia is a consequence of a bone marrow transplant or a stem cell transplant. Such anemias also include anemia of newborn infants. Such anemias also include those which are a consequence of viral, fungal, microbial or parasitic infection.

The compounds of formula I or II are also useful for enhancing normal red blood cell numbers. Such enhancement is desirable for a variety of purposes, especially medical purposes such as preparation of a patient for transfusion and preparation of a patient for surgery.

What is claimed is:

1. A method of inhibiting hYAK3 in a mammal; comprising, administering to the mammal a therapeutically effective amount of a compound of the formula I, or a salt, solvate, or a physiologically functional derivative thereof

Ι

10

5

in which

15 R is C₃₋₆ cycloalkyl or naphtyl; or

R is

20

in which R1 is halogen, -C1-4alkyl, -SC1-4alkyl, -OC1-4alkyl, -NO2, -S(=O)-C1-4alkyl, -OH, -CF3, -CN, -CO2H, or -CQ2C1-4alkyl; and R2 and R3 are independently hydrogen, halogen, -C1-4 alkyl, -SC1-4alkyl, -OC1-4alkyl, -NO2, -S(=O)-C1-4alkyl, -OH, -CF3, -CN, -CO2H, -CO2C1-4alkyl; or

25

R is

in which R4 is hydrogen or -SO₂NH₂; or

R is $\begin{array}{ll} \hbox{-(CH_2)_n-NR^kR^l$ in which n is 2 or 3, and R^k and R^l are independently $-C_{1-4}$ lkyl; or $-NR^kR^l$ together form } \end{array}$

5

10

R is

$$-$$
N, N N,

15

20

Q is

Q is

in which Y is CH or N; and A and B together are a part of

sowesev.lleeoe

TC00001P

provided that ortho position to Y is N or O; or

Q is

in which Y is N br CH; J is OH or -OC1-4alkyl ; L is hydrogen, halogen, NO2, or -OC1-4alkyl.

15

20

25

10

- A method of treating or preventing diseases of the erythroid and hematopoietic systems, caused by the hYAK3 imbalance or inappropriate activity; comprising, administering to a mammal a therapeutically effective amount of a compound of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.
- 3. A method of claim 2 in which diseases of the erythroid and hematopoietic systems are selected from the group consisting of: neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer, and drug-induced anemias; polycythemia; and myelosuppression.
- 4. A method of treating or preventing diseases selected from the group consisting of: neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity or cancer,

5

and drug-induced anemias; polycythemia; and myelosuppression; comprising, administering to a mammal a therapeutically effective amount of a compound of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

5. A method of claims 1, 2, 3 or 4 in which R and Q in a compound of formula I has the following meaning:

10 R is C₃₋₆ cycloalkyl or naphtyl; or

Ris

in which R1 is halogen, -C₁₋₄alkyl, -SC₁₋₄alkyl, -OC₁₋₄alkyl, -NO₂, -S(=O)-C₁₋₄alkyl, -OH, -CF₃, -CN, -CO₂H, or -CO₂C₁₋₄alkyl; and R2 and R3 are independently hydrogen, halogen, -C₁₋₄alkyl, -SC₁₋₄alkyl, -OC₂₋₄alkyl, NO₂₋₂S(-O) O₂₋₄alkyl, ON₂₋₂S(-O) O₃₋₄alkyl, O₃₋₄S(-O) O

-SC14alkyl, -OC14alkyl, -NO2, -S(=O)-C14alkyl, -OH, -CF3, -CN, -CO2H,

20 -CO₂C₁₋₄alkyl; or

R is

in which R4 is hydrogen or -SO₂NH₂; or

R is -(CH₂)_n-NR^kR^l in which n is 2 or 3, and R^k and R^l are independently -C₁₋₄alkyl; or -NR^kR^l together form

$$-N$$
 ; or

35

25

R is

$$-$$
N, N N,

$$-N$$
 ; and

5

15

20

25

35

provided that ortho position to Y is N or O.

10 6. A method of claims 1, 2, 3 or 4 in which a compound of formula I is selected from the group consisting of

Chloro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one;

- 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
 - 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
- 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
- 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one;
- 2-Cyclohexylimino-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one;
- 2-Cyclohexylimino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
 - 5-Benzo[1,3]dioxol-5-ylmethylene-2- (2-chloro-phenylimino)-thiazolidin-4-one;
- 30 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-o-tolylimino-thiazolidin-4-one;
 - 5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-2-o-tolylimino-thiazolidin-4-one;
 - $\hbox{5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-3H-benzooxazol-2-one;}\\$
 - 2-(2-Bromo-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
 - 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;

5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-methylsulfanyl-phenylimino)-thiazolidin-4-one;
5 (9.2 Dibardae hongoffaran-5-vlmethylene)-2-(2-fluoro-phenylimino)-thiazolid

- 5 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-fluoro-phenylimino)-thiazolidin-4-one;
 - $\hbox{$2$-(2-Methylsulfanyl-phenylimino)-5-(quino lin-6-ylmethylene)-thiazolidin-4-one;}$
 - 2-(2-Bromo-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
- 10 2-(2,3-Dimethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
 - 2-(Naphthalen-1-ylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
- 15 5-(Quinolin-6-ylmethylene)-2-(2-trifluoromethyl-phenylimino)-thiazolidin-4-one;
 - $\hbox{2-(2-Chloro-5-trifluoromethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;}$
- 20 2-(2,6-Dichloro-phenylimino)-5-8quinolin-6-ylmethylene)-thiazolidin-4-one;
 - 2-(2-Bromo-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene) -thiazolidin-4-one;
- 25
 5-(Benzo[1,3]dioxol-5-ylmethylene)-2-(2-bromo-phenylimino)-thiazolidin-4-one;
 2-(2-Chloro-phenylimino)-5-(quinoxalin-6-ylmethylene)-thiazolidin-4-one;
- 30 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one;
 - 5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-2-(2-nitro-phenylimino)-thiazolidin-4-one:
- ${\small 5\hbox{-}(2,3\hbox{-}Dihydro-benzo furan-5-ylmethylene)-2-(2-nitro-phenylimino)-thiazolidin-4-one}\\$
 - 2-(2-Chloro-4-fluoro-5-methyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
- 40
 3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid methyl ester;
- 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-45 thiazolidin-4-one;
 - 2-(2-Chloro-4-trifluoromethyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
- 50 2-(4-Bromo-2-chloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)thiazolidin-4-one;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-methanesulfinyl-phenylimino)-

	tmazondin-4-one,
5	3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid;
	5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-1H-pyridin-2-one;
	2-(2-Methylsulfanyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
LO	$2\hbox{-}(2\hbox{-}Chloro\hbox{-}4\hbox{-}fluoro\hbox{-}5\hbox{-}methyl\hbox{-}phenylimino})\hbox{-}5\hbox{-}(quino lin\hbox{-}6\hbox{-}ylmethylene})\hbox{-}thiazolidin\hbox{-}4\hbox{-}one;$
	2-(2-Chloro-5-fluoro-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
15	$\hbox{$2$-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1,4]$ dioxin-6-ylmethylene)-thiazolidin-4-one;}$
	\$2\$-(2-Chloro-\$4-trifluoromethyl-phenylimino)-\$5\$-(quinoxalin-\$6\$-ylmethylene)-thiazolidin-\$4\$-one;
20	5-(Benzothiazol-6-ylmethylene)-2-(2-chloro-phenylimino)-thiazolidin-4-one;
	5-(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-bromo-phenylimino)-thiazolidin-4-one;
25	5-(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-chloro-5-fluoro-phenylimino)-thiazolidira-d-one;
	5-(Benzothiazol-6-ylmethylene)-2-(2,6-dichloro-phenylimino)-thiazolidin-4-one;
30	2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-nitro-benzylidene)-thiazolidin-4-one;
	2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-methoxy-benzylidene)-thiazolidin-4-one;
35	2-(2-Chloro-phenylimino)-5-(4-hydroxy-2-methoxy-benzylidene)-thiazolidin-4-one;
	2-(2-Chloro-phenylimino)-5-(4-hydroxy-benzylidene)-thiazolidin-4-one;
	2-(2-Chloro-phenylimino)-5-(4-methoxy-benzylidene)-thiazolidin-4-one;
40	5-(3-Chloro-4-hydroxy-benzylidene)-2-(2-chloro-phenylimino)-thiazolidin-4-one;
	2-(2-Chloro-phenylimino)-5-(3-fluoro-4-methoxy-benzylidene)-thiazolidin-4-one;
45	2-(2,6-Dichloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;
	2-(2-Chloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;
50	2-(2-Chloro-5-fluoro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;

 $\hbox{\bf 5-(3-Fluoro-4-hydroxy-benzylidene)-2-o-tolylimino-thiazolidin-4-one;}$

- 2-(2-Chloro-phenylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one;
- 5-Quinolin-6-ylmethylene-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one;
- $\hbox{5-Quinolin-6-ylmethylene-2-o-tolylimino-thiazolidin-4-one;}\\$
- 2-(2-Methoxy-phenylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one;
- 5 Benzoic acid N'-(4-oxo-5-quinolin-6-ylmethylene-4,5-dihydro-thiazol-2-yl)-hydrazide;
 - $\hbox{2-(2-Dimethylamino-ethylimino)-5-quino lin-6-ylmethylene-thiazolidin-4-one;}\\$
 - $\hbox{5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(piperidin-1-ylamino)-thiazol-4-one;}\\$
 - 2-Benzylamino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-dimethylamino-ethylamino)-thiazol-4-
- 10 one;
 - 2-(4-tert-Butyl-thiazol-2-ylamino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one;
 - 4-{[5-(2,3-Dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-ylamino]-methyl}-benzenesulfonamide;
- 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(3-dimethylamino-propylamino)-thiazol-4-one;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(3-imidazol-1-yl-propylamino)-thiazol-4-one;
- Phenyl-carbamic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-20 thiazol-2-yl]-hydrazide;
 - and
 - Benzoic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-yl]-hydrazide.
- 25 6. A compound of the formula II, or a salt, solvate, or a physiologically functional derivative thereof,

II

5 in which

R is C₃₋₆ cycloalkyl or naphtyl; or

R is

10

in which R1 is halogen, -C14alkyl, -SC14alkyl, -OC14alkyl, -NO2, -S(=O)-C14alkyl, -OH, -CF3, -CN, -CO2H, or -CO2C14alkyl; and R2 and R3 are independently hydrogen, halogen, -C14alkyl, -SC14alkyl, -OC14alkyl, -NO2, -S(=O)-C14alkyl, -OH, -CF3, -CN, -CO2H, -CO2C14alkyl; or

20

15

R is

in which R4 is hydrogen or -SO2NH2; or

25

R is $-(CH_2)_n$ -NR^kR^l in which n is 2 or 3, and R^k and R^l are independently -C₁₋₄alkyl; or -NR^kR^l together form

R is

$$-N$$
, N , N

$$-N$$
, and

10

5

20

Q is

in which Y is CH or N; and A and B together are a part of

5

10

provided that ortho position to Y is N or O.

7. A pharmaceutical composition including a therapeutically effective amount of a compound claim 6, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. A compound claim 6 or 7 which is selected from the group consisting of:

Chloro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one;

- 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
 2-(2-Chloro-phenylimino)-5-(2-oxo-2H-chromen-6-ylmethylene)-thiazolidin-4-one;
- 20 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one;
- 2-Cyclohexylimino-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)-thiazolidin-4-one;
 25
 2-Cyclohexylimino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-o-tolylimino-thiazolidin-4-one;
- 5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-2-o-tolylimino-thiazolidin-4-one;

 5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-3H-benzooxazol-2-one;

 2-(2-Bromo-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;

 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
 - 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
- 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-methylsulfanyl-phenylimino)-40 thiazolidin-4-one;

5-(2.3-Dihydro-benzofuran	-5-vlmethylene)-2	-(2-fluoro-pher	nylimino)-thiazolidi	n-4-one
---------------------------	-------------------	-----------------	----------------------	---------

- $\hbox{2-(2-Methylsulfanyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;}\\$
- 2-(2-Bromo-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
 - 2-(2,3-Dimethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
- 10 2-(Naphthalen-1-ylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
 - $5\hbox{-}(Quino lin-6-ylmethylene)-2\hbox{-}(2-trifluoromethyl-phenylimino)-thiazolidin-4-one;}$
- 2-(2-Chloro-5-trifluoromethyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4one;
 - 2-(2,6-Dichloro-phenylimino)-5-8quinolin-6-ylmethylene)-thiazolidin-4-one;
- 2-(2-Bromo-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene) -thiazolidin-20 4-one;
 - 2-(2-Chloro-phenylimino)-5-(quinoxalin-6-ylmethylene)-thiazolidin-4-one;
- 2-(2,6-Dichloro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)thiazolidin-4-one;
 - $5\hbox{-}(2,3\hbox{-}Dihydro-benzo \hbox{$[1,4]$ dioxin-6-ylmethylene)-2-(2-nitro-phenylimino)$ -thiazolidin-4-one;}$
- 30 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-nitro-phenylimino)-thiazolidin-4-one;
 - $\hbox{2-(2-Chloro-4-fluoro-5-methyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;}$
- 35 3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid methyl ester;
 - $2\hbox{-}(2\hbox{-}Chloro-5\hbox{-}fluoro-phenylimino})\hbox{-}5\hbox{-}(2\hbox{,}3\hbox{-}dihydro-benzofuran-}5\hbox{-}ylmethylene)\hbox{-}thiazolidin-}4\hbox{-}one;$
- 40 2-(2-Chloro-4-trifluoromethyl-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazolidin-4-one;
- 2-(4-Bromo-2-chloro-phenylimino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-45 thiazolidin-4-one;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-methanesulfinyl-phenylimino)-thiazolidin-4-one;
- 50 3-Chloro-4-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-thiazolidin-2-ylideneamino]-benzoic acid;
 - 5-[2-(2-Chloro-phenylimino)-4-oxo-thiazolidin-5-ylidenemethyl]-1H-pyridin-2-one;

5

2-(2-Methylsulfanyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
--------------------------------------	--

- 2-(2-Chloro-4-fluoro-5-methyl-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
- 2-(2-Chloro-5-fluoro-phenylimino)-5-(quinolin-6-ylmethylene)-thiazolidin-4-one;
- 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethylene)thiazolidin-4-one;
 - $\hbox{$2$-(2-Chloro-4-trifluoromethyl-phenylimino)-5-(quinoxalin-6-ylmethylene)-thiazolidin-4-one;}$
- 5-(Benzothiazol-6-ylmethylene)-2-(2-chloro-phenylimino)-thiazolidin-4-one;
 5-(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-bromo-phenylimino)-thiazolidin-4-one;
- $\begin{array}{lll} & 5\text{-}(Benzo[1,2,5]thiadiazol-5-ylmethylene)-2-(2-chloro-5-fluoro-phenylimino)-thiazolidin-20 & 4-one; \end{array}$
 - 5-(Benzothiazol-6-ylmethylene)-2-(2,6-dichloro-phenylimino)-thiazolidin-4-one;
 - 2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-nitro-benzylidene)-thiazolidin-4-one;
 - 2-(2-Chloro-phenylimino)-5-(4-hydroxy-3-methoxy-benzylidene)-thiazolidin-4-one;
 - $\hbox{2-}(2-Chloro-phenylimino)-5-(4-hydroxy-2-methoxy-benzylidene)-thiazolidin-4-one;$
- 30 2-(2-Chloro-phenylimino)-5-(4-hydroxy-benzylidene)-thiazolidin-4-one;
 - 2-(2-Chloro-phenylimino)-5-(4-methoxy-benzylidene)-thiazolidin-4-one;
- ${\small 5\hbox{-}(3\hbox{-}Chloro\hbox{-}4\hbox{-}hydroxy\hbox{-}benzylidene)\hbox{-}2\hbox{-}(2\hbox{-}chloro\hbox{-}phenylimino)\hbox{-}thiazolidin-}4\hbox{-}one;}$
 - 2-(2-Chloro-phenylimino)-5-(3-fluoro-4-methoxy-benzylidene)-thiazolidin-4-one;
 - $\hbox{2-(2,6-Dichloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;}\\$
- 40 2-(2-Chloro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;
 - 2-(2-Chloro-5-fluoro-phenylimino)-5-(3-fluoro-4-hydroxy-benzylidene)-thiazolidin-4-one;
- 45 5-(3-Fluoro-4-hydroxy-benzylidene)-2-o-tolylimino-thiazolidin-4-one;
 - 5-Quinolin-6-ylmethylene-4-thioxo-thiazolidin-2-one;
 - 2-(2-Chloro-phenylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one;
- 5-Quinolin-6-ylmethylene-2-(2,4,6-trimethyl-phenylimino)-thiazolidin-4-one; 5-Quinolin-6-ylmethylene-2-o-tolylimino-thiazolidin-4-one;

- 2-(2-Methoxy-phenylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one;
- Benzoic acid N'-(4-oxo-5-quinolin-6-ylmethylene-4,5-dihydro-thiazol-2-yl)-hydrazide;
- 2-(2-Dimethylamino-ethylimino)-5-quinolin-6-ylmethylene-thiazolidin-4-one;
- $5\hbox{-}(2,3\hbox{-}Dihydro-benzo furan-}5\hbox{-}ylmethylene)-2\hbox{-}(piperidin-1\hbox{-}ylamino)\hbox{-}thiazol-}4\hbox{-}one;$
- 5 2-Benzylamino-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(2-dimethylamino-ethylamino)-thiazol-4-one:
 - 2-(4-tert-Butyl-thiazol-2-ylamino)-5-(2,3-dihydro-benzofuran-5-ylmethylene)-thiazol-4-one:
- 4-{[5-(2,3-Dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-ylamino]-methyl}-benzenesulfonamide;
 - 5-(2,3-Dihydro-benzofuran-5-ylmethylene)-2-(3-dimethylamino-propylamino)-thiazol-4-one;
 - $5\hbox{-}(2,3\hbox{-}Dihydro-benzo furan-5\hbox{-}ylmethylene)-2\hbox{-}(3\hbox{-}imidaz ol\hbox{-}1\hbox{-}yl\hbox{-}propylamino)-thiaz ol\hbox{-}4\hbox{-}imidaz ol\hbox{-}1\hbox{-}yl\hbox{-}propylamino)-thiaz ol\hbox{-}4\hbox{-}imidaz ol\hbox{-}1\hbox{-}yl\hbox{-}propylamino)-thiaz ol\hbox{-}4\hbox{-}imidaz ol\hbox{-}1\hbox{-}yl\hbox{-}propylamino)-thiaz ol\hbox{-}4\hbox{-}imidaz ol\hbox{-}4\hbox{-}yl\hbox{-}propylamino)$
- 15 one;
 - Phenyl-carbamic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-yl]-hydrazide;
 - and
- Benzoic acid N'-[5-(2,3-dihydro-benzofuran-5-ylmethylene)-4-oxo-4,5-dihydro-thiazol-2-20 yl]-hydrazide.

5

ABSTRACT

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.